Publicaciones en colaboración con investigadores/as de Massachusetts General Hospital (16)

2024

  1. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial

    The Lancet Oncology, Vol. 25, Núm. 5, pp. 588-602

2023

  1. Body composition and lung cancer-associated cachexia in TRACERx

    Nature Medicine, Vol. 29, Núm. 4, pp. 846-858

2022

  1. Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor

    European Journal of Cancer, Vol. 174, pp. S116

2021

  1. Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

    Breast Cancer Research and Treatment, Vol. 189, Núm. 2, pp. 377-386

  2. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

    The Lancet Diabetes and Endocrinology, Vol. 9, Núm. 8, pp. 491-501

2020

  1. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

    Gynecologic Oncology, Vol. 157, Núm. 2, pp. 379-385

2019

  1. Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis

    Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4663-4673

2018

  1. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer

    Gynecologic Oncology, Vol. 151, Núm. 1, pp. 46-52

2017

  1. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer

    Cancer Discovery, Vol. 7, Núm. 12, pp. 1420-1435

  2. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

    The Lancet Oncology, Vol. 18, Núm. 10, pp. 1360-1372

2016

  1. A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer

    Gynecologic Oncology, Vol. 142, Núm. 1, pp. 62-69

2014

  1. Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma

    International Journal of Radiation Oncology Biology Physics, Vol. 88, Núm. 3, pp. 618-623

2012

  1. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: A meta-analysis

    Annals of Oncology, Vol. 23, Núm. 5, pp. 1130-1137

2011

  1. IORT with Electron-Beam, High-Dose-Rate Brachytherapy or Low-KV/Electronic Brachytherapy: Methodological Comparisons

    INTRAOPERATIVE IRRADIATION: TECHNIQUES AND RESULTS, SECOND EDITION (HUMANA PRESS INC), pp. 99-115

  2. Intraoperative Electron Beam Irradiation: Physics and Techniques

    INTRAOPERATIVE IRRADIATION: TECHNIQUES AND RESULTS, SECOND EDITION (HUMANA PRESS INC), pp. 51-72

  3. Primary Colorectal Cancer

    INTRAOPERATIVE IRRADIATION: TECHNIQUES AND RESULTS, SECOND EDITION (HUMANA PRESS INC), pp. 297-322